CENESTIN
ESTROGENS, CONJUGATED SYNTHETIC A
Approval overview CENESTIN is listed in Drugs@FDA under application 020992 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient ESTROGENS, CONJUGATED SYNTHETIC A Form and strength TABLET;ORAL - 0.45MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ASPEN Submission history Latest submission status date: 2026-02-12 00:00:00.
Structured Monograph
Clinical summary
Approval overview CENESTIN is listed in Drugs@FDA under application 020992 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient ESTROGENS, CONJUGATED SYNTHETIC A Form and strength TABLET;ORAL - 0.45MG **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor ASPEN Submission history Latest submission status date: 2026-02-12 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.